|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, GIP stimulates glucagon secretion even at hyperglycemia in people with T2D, suggesting that inappropriate GIPR activity in α-cells contributes to the pathogenesis of T2D.
|
31785304 |
2020 |
|
Hyperglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Similarly, the effect of GIP relative to placebo levels tended to be lower during euglycaemia in ESRD and was significantly reduced during hyperglycaemia (34 [13-50]%, P=0.005).
|
31608934 |
2020 |
|
Hyperglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data support the concept that reduced incretin hormone insulinotropic activity contributes significantly to postprandial hyperglycaemia in cystic fibrosis-related diabetes.
|
31466128 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The attenuating potential of chromenyl chemotype 1 against carbohydrate hydrolyzing enzymes and insulin secretion regulator attributed towards its efficiency as an important natural lead against postprandial hyperglycemia and incretin hormone regulation to maintain glucose homeostasis in the biological system.
|
31353519 |
2019 |
|
Hyperglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
After surgery, indices of IS improved, GIP and glucagon levels decreased significantly in both the groups, while there was no significant change in indices of β-cell function in those with hyperglycaemia.
|
30948746 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Suppression of GIP by pasireotide improved cortisol secretion but produced hyperglycemia.
|
31572300 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sitagliptin, a dipeptidyl peptidase-IV inhibitor (DPP-4), sustains activity of the incretin hormones GLP-1 and GIP and improves hyperglycemia in Type 2 diabetes mellitus (T2DM).
|
29138226 |
2018 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pasireotide-induced hyperglycemia occurs early, within the first 3 months of treatment, due to a decrease in insulin secretion secondary to a fall in secretion of GLP-1 and GIP, and potentially also due to a direct inhibitory effect of pasireotide on beta cells.
|
28579289 |
2017 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, the present study investigated whether the effect of the incretin hormones GLP-1 and GIP differed with regards to the reversal of endothelial cell dysfunction caused by hyperglycemia.
|
28565879 |
2017 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Incretin hormones (glucagon-like peptide-1 [GLP-1] and gastric inhibitory polypeptide [GIP]) may play a role in the development of glucose intolerance and hyperglycemia in patients with hyperthyroidism.
|
28452237 |
2017 |
|
Hyperglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The hyperglycaemia results from beta-cell dysfunction and is associated with lower fasting and stimulated gastric inhibitory polypeptide (GIP) levels.
|
29026101 |
2017 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, a reduced GIP-induced insulin secretion in patients with type 2 diabetes and their first-degree relatives at hyperglycemia is more likely due to a general defect of B-cell function than to a specific defect of the GIP action.
|
14669159 |
2003 |